Evidence Snapshot

NCI-H460

CHEMBL396 CELL-LINE Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:18:43Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:18 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL396

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NCI-H460 as ChEMBL target CHEMBL396. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

NCI-H460

CELL-LINE · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL396

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why NCI-H460 matters

As of 2026-09-13

NCI-H460 is reviewed as NCI-H460; the current evidence base includes 65 approved drugs, 52490 compounds, and 4239 assays, with lead potency reaching pChEMBL 10.6.

Protein context

NCI-H460

Review this target as NCI-H460.

Protein source · UniProt accession via ChEMBL component mapping

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 65 approved drugs, 52490 compounds, and 4239 assays for this target. The dominant activity type is IC50. CHEMBL466114 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL466114 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine

65 approved pChEMBL 10.6

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why NCI-H460 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

52490

Total Compounds

4239

Total Assays

Approved Drugs

IC50: 7613.0, EC50: 193.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL466114	10.6	IC50	—
No preferred name CHEMBL511905	10.6	IC50	—
No preferred name CHEMBL466909	10.6	IC50	—
No preferred name CHEMBL513819	10.6	IC50	—
No preferred name CHEMBL468747	10.6	IC50	—

Approved Drugs

Structure	Compound	First Approval
	TIVOZANIB CHEMBL1289494	2017
	OSIMERTINIB CHEMBL3353410	2015
	CABOZANTINIB S-MALATE CHEMBL2103868	2012
	CABOZANTINIB CHEMBL2105717	2012
	VORINOSTAT CHEMBL98	2006
	ERLOTINIB CHEMBL553	2004
	EPIRUBICIN CHEMBL417	1999
	TOPOTECAN HYDROCHLORIDE CHEMBL1607	1996
	GEMCITABINE HYDROCHLORIDE CHEMBL1637	1996
	GEMCITABINE CHEMBL888	1996
	IRINOTECAN CHEMBL481	1996
	TOPOTECAN CHEMBL84	1996
	DOCETAXEL ANHYDROUS CHEMBL92	1995
	DOCETAXEL CHEMBL3545252	1995
	VINORELBINE CHEMBL553025	1994
	PACLITAXEL CHEMBL428647	1992
	PODOFILOX CHEMBL61	1990
	MITOXANTRONE CHEMBL58	1987
	AMSACRINE CHEMBL43	1987
	ETOPOSIDE CHEMBL44657	1983
	DIGITOXIN CHEMBL254219	1982
	MITOMYCIN CHEMBL105	1981
	DAUNORUBICIN CHEMBL178	1979
	DOXORUBICIN CHEMBL53463	1974
	DOXORUBICIN HYDROCHLORIDE CHEMBL359744	1974
	CYTARABINE CHEMBL803	1969
	VINBLASTINE CHEMBL159	1965
	DACTINOMYCIN CHEMBL1554	1964
	VINCRISTINE CHEMBL90555	1963
	FLUOROURACIL CHEMBL185	1962
	COLCHICINE CHEMBL107	1961
	METHOTREXATE CHEMBL34259	1953

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:18:43Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:18 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL396